Difference between revisions of "Tafasitamab (Monjuvi)"

Code names: MOR208, MOR00208, XmAb5574
Generic name: tafasitamab-cxix
Brand name: Monjuvi

Revision as of 22:23, 3 August 2020

Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity

Abstract: Kami J. Maddocks, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Johannes Duell, Zsolt Nagy, Tomáš Papajík, Marc Andre, Nagesh Kalakonda, Martin H. Dreyling, Pier Luigi Zinzani, Sumeet Vijay Ambarkhane, Johannes Weirather, and Gilles A. Salles. L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study. Journal of Clinical Oncology 2017 35:15_suppl, 7514-7514 link to abstract

7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.

Revision as of 22:23, 3 August 2020 (view source) Jwarner (talk \| contribs) m ← Older edit	Revision as of 22:23, 3 August 2020 (view source) Jwarner (talk \| contribs) m (Jwarner moved page MOR208 to Tafasitamab (Monjuvi): FDA approval) Newer edit →
(No difference)